Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Markolf Hanefeld
Intra-individual variability and circadian rhythm of vascular endothelial growth factors in subjects with normal glucose tolerance and type 2 diabetes
Abstract External IDs PubMed 28991900
Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance
[Skip to Content Landing] Figure 1. STOP-NIDDM Trial Flow Chart IGT, impaired glucose tolerance; STOP-NIDDM, STOP-Noninsulin-Dependent Diabetes Mellitus. Figure 2. Effect of Acarbose on the Probability of Remaining Free of Cardiovascular Disease Figure 3. Effect of Acarbose on the Development of Cardiovascular Disease CI, confidence interval. Asterisk indicates hazard ratio (95% CI) could not be calculated because of zero event for acarbose group. Figure 4.
Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Di
Erratum. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
Reviews in Endocrine and Metabolic Disorders, Volume 17, Issue 1
Volume 17, Issue 1, March 2016 Hanefeld Symposium: 40+ years of Metabolic Syndrome ISSN: 1389-9155 (Print) 1573-2606 (Online) In this issue (14 articles)
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial | Diabetes Care
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial Julio Rosenstock, Bruno Guerci, Markolf Hanefeld, Sandro Gentile, Ronnie Aronson, Francisco J. Tinahones, Christine Roy-Duval, Elisabeth Souhami, Marek Wardecki, Jenny Ye, Riccardo Perfetti, Simon Heller Diabetes Care Aug 2016, 39 (8) 1318-1328; DOI: 10.2337/dc16-0014
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Markolf
Contact Markolf, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack